Spear Dermatology Launches Refissa™

June 4, 2009 Comments
Print

RANDOLPH, N.J.—Spear Dermatology Products Inc. announced Refissa™, a new formulation of tretinoin, was approved by FDA. Refissa is a 0.05 percent prescription-strength, fragrance-free, emollient-based tretinoin cream. The topical creams helps to reduce fine facial wrinkles, rough skin and irregular pigmentation. Refissa's emollient formulation is for patients with normal to dry skin, who should also protect their skin from the sun by wearing a daily sunscreen.

Most dermatologists view topical retinoids as the cornerstone of treatment for sun damaged skin and acne. Most retinoids, however, are formulated and indicated exclusively for the treatment of acne. Among topical retinoids, tretinoin is the "Gold Standard" of treatments and Refissa, formulated in a moisturizing base, is an ideal option for mature patients with drier photo damaged skin.

With the launch of Refissa, Spear Dermatology Productsis well-poised to be at the forefront of the booming prescription topical facial rejuvenation market. Total sales for this market exceeded $394 million in 2002 and increased to more than $494 million in 2007. It is expected that market sales will surpass $513 million by 2012.

Refissa has gone through the extensive testing required to earn FDA approval and offers patients a safe, cost-effective prescription alternative to expensive cosmetic surgery or procedures. A 40-g tube of Refissa may last two to three months, depending on individual usage patterns and costs on average, less than $2.00 per day. Refissa will be available for distribution during the first week of June, 2009.

"Despite the recession, luxury items like skin care and anti-aging products continue to be in high demand," said Stephen Basile, sr. vice president sales and marketing, Spear Dermatology Products Inc. "This growing shift of consumers opting to use less invasive skin rejuvenation products is fueling an ever-growing market for Baby Boomers who want to spend less to effectively treat their sun damaged skin and improve the appearance of their skin."

Refissa contains tretinoin, a derivative of vitamin A, and works deep at the skin's cellular level to increase collagen, which the body produces less of with age. According to K.L. Spear, M.D., dermatologist and president of Spear Dermatology, "Refissa has been proven in a clinical trial to be effective in the treatment of fine facial wrinkles, tactile roughness of the skin, as well as irregular pigmentation from the sun."

 

 

Comments